Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
COVID-19 in Dermatology / / edited by Hazel H. Oon, Chee Leok Goh
| COVID-19 in Dermatology / / edited by Hazel H. Oon, Chee Leok Goh |
| Autore | Oon Hazel H |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (189 pages) |
| Disciplina | 616.5 |
| Altri autori (Persone) | GohChee Leok |
| Collana | Updates in Clinical Dermatology |
| Soggetto topico |
Dermatology
COVID-19 Vacunes Dermatologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-031-45586-X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. The Science of COVID-19 Disease -- Chapter 2. Cutaneous Manifestations of COVID-19 -- Chapter 3. Cutaneous Reactions to COVID-19 mRNA Vaccines -- Chapter 4. Cutaneous Reactions to non mRNA COVID-19 vaccines -- Chapter 5. Evaluation of the Patient With a Coronavirus Disease (COVID-19) Vaccine Cutaneous Reaction -- Chapter 6. Personal Protective Equipment (PPE) related Occupational Dermatoses during COVID 19 -- Chapter 7. COVID-19 OUTBREAK RESPONSE IN DERMATOLOGY -- Chapter 8. Leveraging on teledermatology in the COVID-19 pandemic -- Chapter 9. COVID-19 Dermatology Registries and the Impact of COVID-19 on Dermatology Research -- Chapter 10. Impact of COVID-19 on dermatology medical education -- Chapter 11. Management of immunosuppressed dermatology patients during COVID-19 -- Chapter 12. Therapeutic considerations of COVID-19 on aesthetic dermatology, dermatosurgery and skin cancer -- Chapter 13. Psychological aspects, sychodermatology and vaccine hesitancy during the COVID-19 pandemic -- Chapter 14. Oral COVID-19 Antiviral Agents in Dermatology Outpatient Treatment -- Chapter 15. The Economic Impact of COVID-19 on Dermatology . |
| Record Nr. | UNINA-9910766884403321 |
Oon Hazel H
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Expert review of vaccines
| Expert review of vaccines |
| Pubbl/distr/stampa | London : , : Future Drugs Ltd., , 2002- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Vaccines
Vaccination Vaccins Vacunes |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. Revistes electròniques. |
| ISSN | 1744-8395 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910686495603321 |
| London : , : Future Drugs Ltd., , 2002- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genetic vaccines and therapy
| Genetic vaccines and therapy |
| Pubbl/distr/stampa | [London], : BioMed Central, 2003- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
DNA vaccines
Gene therapy Vaccines, DNA Genetic Therapy Vaccins à ADN Thérapie génique Gene Therapy Teràpia genètica Vacunes |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. Revistes electròniques. |
| ISSN | 1479-0556 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910142912703321 |
| [London], : BioMed Central, 2003- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Human vaccines & immunotherapeutics
| Human vaccines & immunotherapeutics |
| Pubbl/distr/stampa | [Austin, Tex.] : , : Landes Bioscience, , [2012]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 614.4 |
| Soggetto topico |
Vaccines
Immunotherapy Vacunes Immunoteràpia Vaccins Immunothérapie |
| Soggetto genere / forma |
Periodical
Periodicals. Revistes electròniques. |
| ISSN | 2164-554X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Human vaccines and immunotherapeutics
HV&I |
| Record Nr. | UNINA-9910139581303321 |
| [Austin, Tex.] : , : Landes Bioscience, , [2012]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Identification of biomarkers, new treatments, and vaccines for COVID-19 / / Paul C. Guest, editor
| Identification of biomarkers, new treatments, and vaccines for COVID-19 / / Paul C. Guest, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (229 pages) |
| Disciplina | 614.592414 |
| Collana | Advances in experimental medicine and biology |
| Soggetto topico |
COVID-19 (Disease)
COVID-19 Marcadors bioquímics Terapèutica Vacunes |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-71697-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- Part I: Background -- 1: Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement -- 1 Introduction -- 2 Epidemiology -- 3 Main Coronavirus Groups -- 4 Genome, Genotype, and Protein Structure -- 5 Mechanism of Infection -- 6 COVID-19 Pathogenesis -- 7 Respiratory Manifestations -- 8 Extra-pulmonary Presentations -- 8.1 Gastrointestinal Manifestations -- 8.2 Cardiovascular Complications -- 8.3 Haematological Disorders -- 9 Immune Responses -- 10 Therapy -- 10.1 Drugs that Slow Viral Replication or Kill SARS-Cov-2 -- 10.2 Vaccination -- 11 Conclusion -- References -- Part II: Epidemiology -- 2: Prevalence of COVID-19 and the Continued Citizen-Based Control in Japan -- 1 Introduction -- 2 Cruise Ship Outbreak and the Environmental Assessment -- 2.1 COVID-19 Outbreak on the Diamond Princess Cruise Ship -- 2.2 Age-Related CFR Estimated from the Cruise Ship Outbreak -- 2.3 Environmental Assessment of SARS-CoV-2 on the Cruise Ship -- 3 Government-Recommended and Voluntary Measures to Protect Against COVID-19 Infection in Japan -- 4 Detection of the Coronavirus in Laboratories in Japan -- 5 Conclusions -- References -- 3: COVID-19 Pandemic in Brazil: History, Characteristics, and Evolution -- 1 Brief Historical Facts of the COVID-19 Pandemic in Brazil -- 2 Governmental Measures to Combat the Pandemic -- 3 Regional Characteristics Influencing the COVID-19 Dissemination -- 4 Prevalence of the Disease in Different Subpopulations -- 5 Concluding Remarks -- References -- 4: The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study -- 1 Introduction -- 2 Methods -- 2.1 Data Collection -- 2.2 Data Analysis -- 3 Results -- 3.1 Theme I: Emotional-Sensational-Paradox -- Satisfaction-Dissatisfaction -- Positive Experiences-Negative Experiences.
Relaxation-Stress -- Support-Rejection -- 3.2 Theme II: Spiritual Growth -- Accepting and Submitting to Divine Providence -- Rethinking Material Possessions -- Seeking Stronger Divine Connection -- Tendency to Spirituality -- 3.3 Theme III: Experienced Mental-Psychological Effects -- Unpleasant Thoughts -- Perceived Mental Stress -- Positive Thoughts -- 4 Discussion -- 5 Conclusions -- References -- Part III: Risk Factors and Outcomes -- 5: Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons -- 1 Introduction -- 2 Age-Related Effects of Different Infections -- 3 Age Effects of COVID-19 Disease -- 4 Clinical Features in Children -- 5 The Different Etiology and Severity of COVID-19 Based on Age -- 6 Underlying Conditions and Severity of COVID-19 in Children -- 7 Outdoor Activities and the Potential to Contract the Virus -- 8 Immune System and Age-Related Differences -- 9 Innate Immune Cells and Age-Related Differences -- 10 IFN-γ and SARS-CoV in Children -- 11 Adaptive Immune Response and Age-Related Difference -- 12 Cross-Protection Against SARS-CoV-2 and Age-Related Differences -- 13 Improved Efferocytosis by Bacillus Calmette-Guerin (BCG) Vaccine to Protect Against COVID-19 Pneumonia -- 14 Age-Related Difference and Higher Hemoglobin in COVID-19 Pneumonia -- 15 The Role of Sex Hormones and Age-Related Differences in COVID-19 -- 16 Interferon as a Target Therapy in Coronavirus Disease 2019 (COVID-19) -- 17 The Role of Lactoferrin in Immune System Age-Related Differences -- 18 The Recommendations for Selecting Treatment in Patients Based on Age and Neutrophil-to-Lymphocyte Ratio (NLR) -- 19 Conclusions -- References -- 6: Sex Differences and COVID-19 -- 1 Introduction -- 1.1 COVID-19 -- 1.2 Sex and the COVID-19 Response. 2 Physiological Sex Differences as Potential Moderators of COVID-19 Outcomes -- 2.1 The Immune System and COVID-19 -- 2.2 Sex Differences in the Immune System -- 2.3 Sex Hormones and the Immune Response -- 2.4 Sex Hormones and COVID-19 -- 2.5 Sex Chromosomes and the Immune System -- 2.6 Ageing, Sex and the Immune System -- 3 Sex Differences in the Renin-Angiotensin-Aldosterone System -- 3.1 Sex Differences in the Renin-Angiotensin System and COVID-19 -- 4 Reproduction, Pregnancy and COVID-19 -- 5 Long-Term Outcomes of COVID-19 and Sex Differences -- 6 Conclusion and Perspectives -- References -- 7: Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? -- 1 Introduction -- 1.1 Epidemiological Characteristics of Coronavirus Diseases -- 1.2 Coronavirus Disease 2019 (COVID-19) -- 2 Microbiota and Respiratory Infection -- 3 Potential Connections Between Intestinal Microbiota and COVID-19 -- 3.1 Age Effects -- 3.2 Hypertension -- 3.3 Diabetes -- 3.4 Obesity -- 4 COVID-19 and Microbiota -- 5 Conclusions and Future Perspectives -- References -- 8: SARS-CoV-2 Infection and the Kidneys: An Evolving Picture -- 1 Introduction -- 2 Dialysis -- 3 Transplant -- 4 Chronic Kidney Disease -- 5 Apo L1 -- 6 The Clinical Picture of Kidney Disease in COVID-19 -- 6.1 Acute Kidney Injury Pathophysiology -- 7 Conclusions -- References -- 9: Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information -- 1 Introduction -- 2 Exanthem Pattern -- 2.1 Vesicular Eruptions or Varicella-Like Exanthem -- 2.2 Maculopapular Eruptions or Maculopapular Rash -- 3 Urticarial Lesions -- 4 Vascular Pattern -- 4.1 Acral Areas of Erythema with Vesicles or Pustules (Pseudo-Chilblain) -- 4.2 Purpuric/Petechial Lesions -- 4.3 Livedo or Necrosis -- 5 Acro-Papular Eruption -- 6 Treatment -- 7 Pathophysiological Mechanisms. 8 Conclusions -- References -- 10: How Do We Manage Breastfeeding During the COVID-19 Pandemic? -- 1 Introduction -- 2 Benefits of Breastfeeding -- 3 COVID-19 and Breastfeeding: Current Evidence -- 4 Guidelines on Breastfeeding for Mothers with Suspected or Confirmed COVID-19 -- 5 Conditions Recommended for Starting and Maintaining Breastfeeding -- 6 Conditions in Which It Is Recommended to Extract Breast Milk -- 7 Conditions in Which Recommended for Not Breastfeeding or Extracting Breast Milk -- 8 Breastfeeding by Mothers Undergoing Medications for COVID-19 -- 9 Conclusions and Future Perspectives -- References -- 11: Deep Learning Analysis in Prediction of COVID-19 Infection Status Using Chest CT Scan Features -- 1 Introduction -- 2 Methods -- 2.1 Study Design and Participants -- 2.2 CT Examination and Image Analysis -- 2.3 Statistical Analysis -- Comparisons Between Two Groups -- Deep Learning Analyzing and Classification -- 3 Results -- 3.1 Demographic Characteristics and Chest CT Findings -- 3.2 Deep Learning Analyzing Results -- 4 Discussion -- 5 Conclusions -- References -- Part IV: Treatments and Vaccines -- 12: Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review -- 1 Introduction -- 2 Methods -- 2.1 Inclusion Criteria -- 2.2 Search Strategy -- 3 Results -- 3.1 Extraction of Results -- 3.2 Protocols -- 3.3 Mechanism of Ozone as a Treatment -- 3.4 Ozone Therapy and Viral Infections -- 3.5 Ozone Therapy and Respiratory System -- Asthma -- Chronic Obstructive Pulmonary Disease (COPD) -- Pulmonary Emphysema -- 4 Discussion -- 5 Conclusions and Future Perspective -- References -- 13: COVID-19, Coenzyme Q10 and Selenium -- 1 Introduction -- 2 CoQ10 -- 3 Selenium -- 4 Oxidative Stress, Inflammation and Virus Infection -- 4.1 Oxidative Stress -- 4.2 Inflammation. 5 Supplementation CoQ10 and Selenium -- 6 Conclusions and Future Perspectives -- References -- 14: Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19) -- 1 Introduction -- 2 Agents with Known Effect Against SARS-CoV-2 -- 2.1 Alcohol and Isopropanol -- 2.2 Povidone-Iodine -- 2.3 Hydrogen Peroxide -- 2.4 Ultraviolet (UV) Radiation -- 2.5 Xylitol -- 2.6 Brilacidin -- 2.7 Carrageenan -- 3 Agents with Potential Effect on SARS-CoV-2 -- 3.1 Acid-Buffered Saline -- 3.2 Hypertonic Saline -- 3.3 Oxymetazoline and Xylometazoline -- 3.4 Probiotics -- 3.5 Chlorhexidine -- 3.6 Citrox (Flavonoids) and Cyclodextrins -- 3.7 Cetylpyridinium Chloride (CPC) -- 3.8 Surfactants/Shampoo -- 3.9 Interferon -- 4 Therapeutic Application and Method of Delivery -- 5 Conclusions -- References -- 15: Cinnamon: A Promising Natural Product Against COVID-19 -- 1 Introduction -- 2 Antiallergic Properties -- 3 Antiviral Properties -- 4 Cardiovascular Properties -- 5 Safety of Cinnamon -- 6 Conclusions and Future Perspectives -- References -- 16: Curcumin and Piperine in COVID-19: A Promising Duo to the Rescue? -- 1 Introduction -- 2 Curcumin-Piperine -- 3 Curcumin-Piperine and Virus-Induced Lung Injury -- 4 Curcumin-Piperine and Thrombosis -- 5 Safety of Curcumin-Piperine -- 6 Conclusions and Future Perspectives -- References -- 17: Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19 -- 1 Introduction -- 2 Methods -- 2.1 Study Design and Participants -- 2.2 Data Collection -- 2.3 Medication -- 2.4 Outcomes -- 2.5 Statistical Analysis -- 3 Results -- 4 Discussion -- 5 Conclusion -- References -- 18: The Worldwide Effort to Develop Vaccines for COVID-19 -- 1 Introduction -- 2 The SARS-CoV-2 Spike Protein. 3 SARS-CoV-2 Vaccine Candidates in Phase 3 Clinical Trials. |
| Record Nr. | UNINA-9910495243103321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Journal of immune based therapies and vaccines
| Journal of immune based therapies and vaccines |
| Pubbl/distr/stampa | [London], : BioMed Central, ©2003-2011 |
| Soggetto topico |
Immunotherapy
Immunology Pharmacology Immunothérapie Vaccins Vaccines Immunoteràpia Vacunes |
| Soggetto genere / forma |
Fulltext
Internet Resources. Periodicals. Periodical Revistes electròniques. |
| Soggetto non controllato | Pharmacy, Therapeutics, & Pharmacology |
| ISSN | 1476-8518 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | JIBTV |
| Record Nr. | UNISA-996197565203316 |
| [London], : BioMed Central, ©2003-2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Nanoparticles for rational vaccine design / / Harvinder Singh Gill, Richard W. Compans, editors
| Nanoparticles for rational vaccine design / / Harvinder Singh Gill, Richard W. Compans, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (140 pages) |
| Disciplina | 615.372 |
| Collana | Current topics in microbiology and immunology |
| Soggetto topico |
Vaccines - Design
Vacunes Immunoteràpia Nanopartícules Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-85067-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495172503321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel vaccination strategies [[electronic resource] /] / edited by Stefan H.E. Kaufmann
| Novel vaccination strategies [[electronic resource] /] / edited by Stefan H.E. Kaufmann |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2004 |
| Descrizione fisica | 1 online resource (672 p.) |
| Disciplina | 615.372 |
| Altri autori (Persone) | KaufmannS. H. E (Stefan H. E.) |
| Soggetto topico |
Vaccines
Vaccines - Synthesis Vacunes Vacunació Resposta immunitària |
| Soggetto genere / forma |
Electronic books.
Llibres electrònics |
| ISBN |
1-280-72268-1
9786610722686 3-527-60609-2 1-280-55857-1 9786610558575 3-527-60144-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Novel Vaccination Strategies; Contents; Novel Vaccination Strategies; Preface; Acknowledgements; List of Contributors; Colour Plates; Part I; 1 Challenges for the Vaccine Developer, including Correlates of Protection; 1.1 Introduction; 1.2 Mechanisms of Protection within the Immune System; 1.3 Protection against Viruses; 1.4 HIV/AIDS as an Example of a Persisting Virus; 1.5 Protection against Extracellular Bacteria; 1.6 Protection against Intracellular Bacteria; 1.7 Protection against Parasites; 1.8 Conclusions; References; Part II Vaccination and Immune Response
2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses2.1 Introduction; 2.2 Activation of Innate Immunity: Sensing the Enemy; 2.2.1 Pathogen-associated Molecular Patterns; 2.2.2 Host Cellular Sensors; 2.2.2.1 Dendritic Cells; 2.2.2.2 Mast Cells; 2.2.3 Nonpeptide MHC Ligands Triggering Invariant T-cell Receptors; 2.3 Translating Innate Immune Activation into Regulatory Circuits: Molecular Pathways Shaping Adaptive Immunity; 2.3.1 TLR-initiated Signaling Cascades; 2.3.2 Molecules Involved in Recruiting Effector Cells; 2.3.2.1 Defensins; 2.3.2.2 Chemokines 2.3.3 Molecules Involved in T and B Cell Differentiation2.3.3.1 Th1-inducing Cytokines; 2.3.3.2 Th2-inducing Cytokines; 2.4 Implications for Vaccine Development; References; 3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination; 3.1 Introduction; 3.2 The Two-Signal Model of Adjuvant-induced Immune Activation; 3.3 Th1 and Th2 Induction by Vaccine Adjuvants; 3.4 Antigen Dose Effects; 3.5 The Three-signal Model of Adjuvant-induced Immune Activation; 3.6 Th2 Induction by Adjuvants; 3.7 Differential Activation of DCs; 3.8 Inappropriate Th1/Th2 Responses to Vaccines 3.9 Human Th2 vaccines3.10 Human Th1 Vaccines; 3.11 Conclusion; References; 4 Memory; 4.1 Introduction; 4.2 Characteristics of Memory Cells; 4.3 CD8+ T Cell Memory; 4.3.1 Phenotyping Memory CD8+ T Cells; 4.3.2 Enhanced Responsiveness of Memory CD8(+) T cells: Potential Mechanisms; 4.3.3 Generation of Memory CD8+ T Cells; 4.3.4 Maintaining CD8+ T Cell Memory; 4.3.5 Models of CD8+ T cell Memory Generation; 4.4 CD4+ T Cell Memory; 4.4.1 Differentiation of Effector and Memory CD4+ T Cells; 4.4.2 Phenotype of Memory CD4+ T Cells; 4.4.3 Memory Generation and Maintenance 4.4.4 Trafficking of Memory CD4+ T Cells4.5 B cell Memory; 4.5.1 Generation of B Cell Memory; 4.5.2 Maintenance of B Cell Memory; 4.6 Conclusions; Acknowledgements; References; 5 T Cell-based Vaccines; Summary; 5.1 Introduction; 5.2 Ex-vivo Detection of Antigen-specific T Cells; 5.3 In-vivo Kinetics of Antigen-specific T Cell Responses; 5.4 Effector Function and Subtypes of Effector T Cells; 5.5 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition; 5.6 Functional Heterogeneity of T Cell Memory; 5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination 5.8 Concluding Remarks |
| Record Nr. | UNINA-9910146240503321 |
| Weinheim, : Wiley-VCH, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel vaccination strategies [[electronic resource] /] / edited by Stefan H.E. Kaufmann
| Novel vaccination strategies [[electronic resource] /] / edited by Stefan H.E. Kaufmann |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2004 |
| Descrizione fisica | 1 online resource (672 p.) |
| Disciplina | 615.372 |
| Altri autori (Persone) | KaufmannS. H. E (Stefan H. E.) |
| Soggetto topico |
Vaccines
Vaccines - Synthesis Vacunes Vacunació Resposta immunitària |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
1-280-72268-1
9786610722686 3-527-60609-2 1-280-55857-1 9786610558575 3-527-60144-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Novel Vaccination Strategies; Contents; Novel Vaccination Strategies; Preface; Acknowledgements; List of Contributors; Colour Plates; Part I; 1 Challenges for the Vaccine Developer, including Correlates of Protection; 1.1 Introduction; 1.2 Mechanisms of Protection within the Immune System; 1.3 Protection against Viruses; 1.4 HIV/AIDS as an Example of a Persisting Virus; 1.5 Protection against Extracellular Bacteria; 1.6 Protection against Intracellular Bacteria; 1.7 Protection against Parasites; 1.8 Conclusions; References; Part II Vaccination and Immune Response
2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses2.1 Introduction; 2.2 Activation of Innate Immunity: Sensing the Enemy; 2.2.1 Pathogen-associated Molecular Patterns; 2.2.2 Host Cellular Sensors; 2.2.2.1 Dendritic Cells; 2.2.2.2 Mast Cells; 2.2.3 Nonpeptide MHC Ligands Triggering Invariant T-cell Receptors; 2.3 Translating Innate Immune Activation into Regulatory Circuits: Molecular Pathways Shaping Adaptive Immunity; 2.3.1 TLR-initiated Signaling Cascades; 2.3.2 Molecules Involved in Recruiting Effector Cells; 2.3.2.1 Defensins; 2.3.2.2 Chemokines 2.3.3 Molecules Involved in T and B Cell Differentiation2.3.3.1 Th1-inducing Cytokines; 2.3.3.2 Th2-inducing Cytokines; 2.4 Implications for Vaccine Development; References; 3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination; 3.1 Introduction; 3.2 The Two-Signal Model of Adjuvant-induced Immune Activation; 3.3 Th1 and Th2 Induction by Vaccine Adjuvants; 3.4 Antigen Dose Effects; 3.5 The Three-signal Model of Adjuvant-induced Immune Activation; 3.6 Th2 Induction by Adjuvants; 3.7 Differential Activation of DCs; 3.8 Inappropriate Th1/Th2 Responses to Vaccines 3.9 Human Th2 vaccines3.10 Human Th1 Vaccines; 3.11 Conclusion; References; 4 Memory; 4.1 Introduction; 4.2 Characteristics of Memory Cells; 4.3 CD8+ T Cell Memory; 4.3.1 Phenotyping Memory CD8+ T Cells; 4.3.2 Enhanced Responsiveness of Memory CD8(+) T cells: Potential Mechanisms; 4.3.3 Generation of Memory CD8+ T Cells; 4.3.4 Maintaining CD8+ T Cell Memory; 4.3.5 Models of CD8+ T cell Memory Generation; 4.4 CD4+ T Cell Memory; 4.4.1 Differentiation of Effector and Memory CD4+ T Cells; 4.4.2 Phenotype of Memory CD4+ T Cells; 4.4.3 Memory Generation and Maintenance 4.4.4 Trafficking of Memory CD4+ T Cells4.5 B cell Memory; 4.5.1 Generation of B Cell Memory; 4.5.2 Maintenance of B Cell Memory; 4.6 Conclusions; Acknowledgements; References; 5 T Cell-based Vaccines; Summary; 5.1 Introduction; 5.2 Ex-vivo Detection of Antigen-specific T Cells; 5.3 In-vivo Kinetics of Antigen-specific T Cell Responses; 5.4 Effector Function and Subtypes of Effector T Cells; 5.5 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition; 5.6 Functional Heterogeneity of T Cell Memory; 5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination 5.8 Concluding Remarks |
| Record Nr. | UNINA-9910830702203321 |
| Weinheim, : Wiley-VCH, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel vaccination strategies / / edited by Stefan H.E. Kaufmann
| Novel vaccination strategies / / edited by Stefan H.E. Kaufmann |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2004 |
| Descrizione fisica | 1 online resource (672 p.) |
| Disciplina | 615.372 |
| Soggetto topico |
Vaccines
Vaccines - Synthesis Vacunes Vacunació Resposta immunitària |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9786610722686
9786610558575 9781280722684 1280722681 9783527606092 3527606092 9781280558573 1280558571 9783527601448 3527601449 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Novel Vaccination Strategies; Contents; Novel Vaccination Strategies; Preface; Acknowledgements; List of Contributors; Colour Plates; Part I; 1 Challenges for the Vaccine Developer, including Correlates of Protection; 1.1 Introduction; 1.2 Mechanisms of Protection within the Immune System; 1.3 Protection against Viruses; 1.4 HIV/AIDS as an Example of a Persisting Virus; 1.5 Protection against Extracellular Bacteria; 1.6 Protection against Intracellular Bacteria; 1.7 Protection against Parasites; 1.8 Conclusions; References; Part II Vaccination and Immune Response
2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses2.1 Introduction; 2.2 Activation of Innate Immunity: Sensing the Enemy; 2.2.1 Pathogen-associated Molecular Patterns; 2.2.2 Host Cellular Sensors; 2.2.2.1 Dendritic Cells; 2.2.2.2 Mast Cells; 2.2.3 Nonpeptide MHC Ligands Triggering Invariant T-cell Receptors; 2.3 Translating Innate Immune Activation into Regulatory Circuits: Molecular Pathways Shaping Adaptive Immunity; 2.3.1 TLR-initiated Signaling Cascades; 2.3.2 Molecules Involved in Recruiting Effector Cells; 2.3.2.1 Defensins; 2.3.2.2 Chemokines 2.3.3 Molecules Involved in T and B Cell Differentiation2.3.3.1 Th1-inducing Cytokines; 2.3.3.2 Th2-inducing Cytokines; 2.4 Implications for Vaccine Development; References; 3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination; 3.1 Introduction; 3.2 The Two-Signal Model of Adjuvant-induced Immune Activation; 3.3 Th1 and Th2 Induction by Vaccine Adjuvants; 3.4 Antigen Dose Effects; 3.5 The Three-signal Model of Adjuvant-induced Immune Activation; 3.6 Th2 Induction by Adjuvants; 3.7 Differential Activation of DCs; 3.8 Inappropriate Th1/Th2 Responses to Vaccines 3.9 Human Th2 vaccines3.10 Human Th1 Vaccines; 3.11 Conclusion; References; 4 Memory; 4.1 Introduction; 4.2 Characteristics of Memory Cells; 4.3 CD8+ T Cell Memory; 4.3.1 Phenotyping Memory CD8+ T Cells; 4.3.2 Enhanced Responsiveness of Memory CD8(+) T cells: Potential Mechanisms; 4.3.3 Generation of Memory CD8+ T Cells; 4.3.4 Maintaining CD8+ T Cell Memory; 4.3.5 Models of CD8+ T cell Memory Generation; 4.4 CD4+ T Cell Memory; 4.4.1 Differentiation of Effector and Memory CD4+ T Cells; 4.4.2 Phenotype of Memory CD4+ T Cells; 4.4.3 Memory Generation and Maintenance 4.4.4 Trafficking of Memory CD4+ T Cells4.5 B cell Memory; 4.5.1 Generation of B Cell Memory; 4.5.2 Maintenance of B Cell Memory; 4.6 Conclusions; Acknowledgements; References; 5 T Cell-based Vaccines; Summary; 5.1 Introduction; 5.2 Ex-vivo Detection of Antigen-specific T Cells; 5.3 In-vivo Kinetics of Antigen-specific T Cell Responses; 5.4 Effector Function and Subtypes of Effector T Cells; 5.5 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition; 5.6 Functional Heterogeneity of T Cell Memory; 5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination 5.8 Concluding Remarks |
| Record Nr. | UNINA-9911019996603321 |
| Weinheim, : Wiley-VCH, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Vacunes
(12)
- Vaccines (7)
- COVID-19 (3)
- Immunoteràpia (3)
- Resposta immunitària (3)